Additional Supporting Information may be found in the online version of this article.

HEP_26255_sm_SuppFig1.tif695KSupporting Information Figure 1.
HEP_26255_sm_SuppFig2.tif1133KSupporting Information Figure 2.
HEP_26255_sm_SuppFig3.tif710KSupporting Information Figure 3.
HEP_26255_sm_SuppFig4.tif2476KSupporting Information Figure 4.
HEP_26255_sm_SuppTab1.doc76KSupporting Information Table 1. siRNA target sequences.
HEP_26255_sm_SuppTab2.doc44KSupporting Information Table 2. Sequence of primers for RT-PCR and qRT-PCR.
HEP_26255_sm_SuppTab3.doc70KSupporting Information Table 3. Primary antibodies for western blot, IHC and co-IP.
HEP_26255_sm_SuppTab4.doc72KSupporting Information Table 4. Correlation between Cryab and clinicopathological characteristics in 403 HCCs.
HEP_26255_sm_SuppTab5.doc164KSupporting Information Table 5. The signifacant pathways related to Cryab based on the data base KEGG and Biocarta respectively.
HEP_26255_sm_SuppTab6.doc47KSupporting Information Table 6. Demographic and Baseline Characteristics of the Patients (Sorafenib-Treated Population).
HEP_26255_sm_SuppTab7.doc47KSupporting Information Table 7. HCCLM3 LC-MS protein associated with MAPK.
HEP_26255_sm_SuppTab8.doc45KSupporting Information Table 8. Hep3B-Cryab LC-MS protein associated with MAPK.
HEP_26255_sm_SuppInfo.doc39KSupporting Information

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.